19,128 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Bought by Intech Investment Management LLC

Intech Investment Management LLC acquired a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 19,128 shares of the company’s stock, valued at approximately $861,000.

A number of other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in shares of Protagonist Therapeutics by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 3,192,971 shares of the company’s stock worth $92,373,000 after buying an additional 39,055 shares during the last quarter. New York State Teachers Retirement System bought a new stake in Protagonist Therapeutics in the third quarter worth about $1,107,000. Seven Eight Capital LP raised its position in Protagonist Therapeutics by 426.9% in the second quarter. Seven Eight Capital LP now owns 36,793 shares of the company’s stock worth $1,275,000 after acquiring an additional 29,810 shares during the period. Bank of New York Mellon Corp grew its position in shares of Protagonist Therapeutics by 9.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 204,299 shares of the company’s stock valued at $7,079,000 after acquiring an additional 17,065 shares during the period. Finally, Dark Forest Capital Management LP bought a new position in shares of Protagonist Therapeutics during the 2nd quarter valued at approximately $2,112,000. Institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Stock Performance

NASDAQ:PTGX opened at $44.95 on Friday. Protagonist Therapeutics, Inc. has a 52-week low of $17.13 and a 52-week high of $48.89. The stock has a fifty day moving average of $45.22 and a 200 day moving average of $39.66. The firm has a market capitalization of $2.68 billion, a price-to-earnings ratio of 16.90 and a beta of 2.17.

Insider Buying and Selling at Protagonist Therapeutics

In other news, insider Arturo Md Molina sold 1,906 shares of the firm’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $40.98, for a total transaction of $78,107.88. Following the sale, the insider now owns 46,444 shares in the company, valued at approximately $1,903,275.12. This trade represents a 3.94 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director William D. Waddill sold 8,000 shares of the company’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $45.00, for a total transaction of $360,000.00. Following the completion of the transaction, the director now owns 12,000 shares of the company’s stock, valued at $540,000. This trade represents a 40.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 232,066 shares of company stock valued at $10,681,738 in the last 90 days. Corporate insiders own 5.40% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on PTGX shares. Truist Financial began coverage on Protagonist Therapeutics in a research note on Monday, September 9th. They issued a “buy” rating and a $60.00 price objective on the stock. Wedbush reaffirmed an “outperform” rating and set a $58.00 price target on shares of Protagonist Therapeutics in a research report on Tuesday, November 19th. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Protagonist Therapeutics in a report on Tuesday, November 19th. StockNews.com raised shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Finally, TD Cowen upgraded shares of Protagonist Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 25th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $53.57.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.